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Metabolic Inhibitors of O-GlcNAc Transferase That Act In Vivo
Implicate Decreased O-GlcNAc Levels in Leptin-Mediated Nutrient
Sensing
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Xiaoyang Shan, and David J. Vocadlo*
Abstract: O-Linked glycosylation of serine and threonine
residues of nucleocytoplasmic proteins with N-acetylglucos-
amine (O-GlcNAc) residues is catalyzed by O-GlcNAc trans-
ferase (OGT). O-GlcNAc is conserved within mammals and is
implicated in a wide range of physiological processes. Herein,
we describe metabolic precursor inhibitors of OGT suitable for
use both in cells and in vivo in mice. These 5-thiosugar
analogues of N-acetylglucosamine are assimilated through
a convergent metabolic pathway, most likely involving
N-acetylglucosamine-6-phosphate de-N-acetylase (NAGA),
to generate a common OGT inhibitor within cells. We show
that of these inhibitors, 2-deoxy-2-N-hexanamide-5-thio-d-
glucopyranoside (5SGlcNHex) acts in vivo to induce dose-
and time-dependent decreases in O-GlcNAc levels in various
tissues. Decreased O-GlcNAc correlates, both in vitro within
adipocytes and in vivo within mice, with lower levels of the
transcription factor Sp1 and the satiety-inducing hormone
leptin, thus revealing a link between decreased O-GlcNAc
levels and nutrient sensing in peripheral tissues of mammals.
The dynamic modification of nucleocytoplasmic proteins
with b-O-linked N-acetylglucosamine (O-GlcNAc) is present
in all multicellular eukaryotes.[1] The attachment of GlcNAc
(1, Figure 1) to hydroxy groups of serine or threonine residues
of hundreds of target proteins is catalyzed by the glycosyl-
transferase O-GlcNAc transferase (OGT), which uses uridine
diphospho-N-acetylglucosamine (UDP-GlcNAc, 2) as
a donor sugar substrate. The glycosidase O-GlcNAcase
(OGA) cleaves O-GlcNAc off from proteins.
O-GlcNAc is implicated in various diseases including
cancer, neurodegeneration, cardiovascular disease, and obe-
sity.[2] Notably, O-GlcNAc levels respond to nutrient avail-
ability both within cells and in vivo in animal models.[1b]
Transgenic mice overexpressing OGT in fat or muscle tissue
exhibit elevated serum leptin and insulin levels in addition to
insulin resistance.[3] Furthermore, deletion of the gene
encoding OGT from neurons of the paraventricular nucleus
(PVN) within the hypothalamus of mice results in uncon-
trolled eating.[2b]
Notably, OGA inhibitors that are active in vivo have
helped gain insight into the roles of increased O-GlcNAc
levels in mammals. Strikingly, OGA inhibitors sometimes
Figure 1. The hexosamine biosynthetic pathway (HBP) and the GlcNAc
salvage pathway yield UDP-GlcNAc (2). Glutamine fructose amido-
transferase (GFAT) catalyzes the conversion of glucosamine (5) into
glucosamine-6-phosphate (GlcNH2-6PO4 ; 5-6PO4). Acetylation of
5-6PO4 by glucosamine acetyltransferase (GAT) yields GlcNAc-6PO4,
an intermediate also produced by GlcNAc kinase (GNK) in the GlcNAc
salvage pathway. The sequential action of phosphoglucosamine
mutase (AGM) and GlcNAc pyrophosphorylase (AGX) on GlcNAc-
6PO4 leads to the formation of UDP-GlcNAc (2). 5SGlcNAc (3) can be
similarly salvaged and converted into UDP-5SGlcNAc (4).
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yield different results from those made using genetic
approaches to increase O-GlcNAc levels,[4] perhaps because
OGT and OGA also have non-catalytic roles. Unfortunately,
similar studies regarding the influence of decreased
O-GlcNAc on mammalian physiology are lacking because
there are noOGT inhibitors suitable for use in vivo. Given the
emerging roles of OGT in nutrient sensing and other
processes, inhibitors of OGT that can be used as research
tools in vivo are of high interest.[5]
One approach to decreasing O-GlcNAc levels using small
molecules has been to use broad-spectrum amidotransferase
inhibitors such as 6-diazo-5-oxo-l-norleucine (DON), which
promiscuously blocks all amidotransferases that biosynthe-
size many cellular metabolites including UDP-GlcNAc. High-
throughput screening has been pursued to deliver hits that can
be improved upon.[5b,d] These leads, however, show modest
cellular activity and limited solubility.[5b] They also exhibit off-
target cellular toxicity.[5b] Another approach[5c] has been to
generate a GlcNAc analogue, 2-acetamido-2-deoxy-5-thio-a-
d-glucopyranose (5SGlcNAc, 3), which in its per-O-acety-
lated form (Ac45SGlcNAc, 3-OAc) can diffuse across the
plasma membrane. Within cells, 3-OAc is de-O-acetylated
and assimilated via the GlcNAc salvage pathway (Figure 1) to
generate UDP-5SGlcNAc (4), which is a competitive OGT
inhibitor (Ki= 8 mm). 3-OAc lowers cellular O-GlcNAc levels
(EC50= 0.8–5 mm). This metabolic OGT inhibitor is not toxic
but suffers from poor solubility in aqueous solution. Indeed,
while often used in cell studies,[6] solubilizing 3-OAc requires
high concentrations of DMSO, making it incompatible for
dosing of mammals. Accordingly, to explore the roles of
decreased O-GlcNAc levels in organismal physiology, com-
pounds that act in vivo are of high interest.
To generate a tool compound for inhibiting OGT in vivo,
we synthesized a panel of water-soluble analogues of
5SGlcNAc (3) possessing various N-acyl substituents (7–17;
Figure 2a,b and Scheme S1 in the Supporting Information).
We reasoned that these hydrophobic N-acyl groups would
confer a balance between hydrophilicity and lipophilicity,
making them water-soluble yet able to diffuse into cells.
Furthermore, although the substrate specificity of N-acetyl-
glucosamine-6-phosphate de-N-acetylase (NAGA) is not
known,[7] we speculated that compounds 7–17, once phos-
phorylated, might be substrates for this recently identified
enzyme (Figure 2b). Action of NAGA on phosphorylated 7–
17 would lead to formation of a common intermediate,
5-thioglucosamine-6-phosphate (5-6PO4), which can be
assimilated by the hexosamine biosynthetic pathway (HBP).
However, direct entry of 7–17 into the GlcNAc salvage
pathway cannot be ruled out as the specificity of NAGA is
unknown, and bulkier N-glycolyl (GlcNGc)- and N-azidoa-
cetyl (GlcNAz)-containing analogues enter the HBP.[8]
To measure the potential of 7–17 and their per-O-
acetylated congeners to block OGT activity in cells, we
treated cells with these compounds. Analysis of O-GlcNAc
levels of cell lysates showed that only some deprotected
analogues were effective in reducing O-GlcNAc levels (Fig-
ure 2c and Figure S1). Of these, the promising 2-hexanamide
derivative (5SGlcNHex, 12) showed dose-dependent
decreases in O-GlcNAc comparable to those achieved with
Ac45SGlcNAc (3-OAc; Figure S2).
We next tested whether these compounds were directly
activated as UDP-linked analogues or if they were metabo-
lized by NAGA.We therefore analyzed the pool of nucleotide
sugars from cells treated with compounds 7, 8, and 12 by
capillary electrophoresis (CE; Figure 3). Electropherograms
for nucleotide sugars from cells treated with 7, 8, and 12
revealed two new peaks with CE mobilities matching those of
the chemoenzymatically prepared standards UDP-5SGlcNAc
(4) and its epimer UDP-5SGalNAc (Figure 3a). Extracts
from cells treated with per-O-acetylated 5SGlcNH2 (6-OAc,
Figure S3) also yielded the same two unnatural nucleotide
sugars in cells. These data suggest that these 5SGlcNR
analogues are processed within cells to the common inter-
mediate 2-amino-2-deoxy-5-thioglucopyranose 6-phosphate
(6-PO4) and then assimilated by the HBP to form UDP-
5SGlcNAc (4).
To clarify the metabolic processing of compounds 7, 8, and
12, we used recombinant enzymes of the mammalian HBP
(Figure 1). Compounds 7, 8, and 12 were all phosphorylated
by GNK (Figure 3b), yet none of the phosphorylated
products were substrates for AGM except for 7. However,
the nucleotide sugar produced in vitro from 7 by the
combined HBP enzymes had a different mobility than
nucleotide sugar UDP-5SGlcNAc (4), which we detected in
cells treated with compound 7 (Figure S4). We accordingly
tested whether NAGA converted the corresponding
5-thiosugar-6-PO4 derivatives of 7, 8, and 12 into 5SGlcNH2-
6-PO4 (6-6PO4). We confirmed this scenario by digestion of
12-PO4 with recombinant human NAGA. Electropherograms
obtained by CE analysis of the processing of 12-PO4 by
NAGA showed that this compound was converted into
5SGlcNH2-6-PO4 (6-PO4 ; Figure 3c). These data suggest
that the 5SGlcNR analogues 7–17, including 7, 8, and the
most potent derivative 5SGlcNHex (12), are phosphorylated
within cells by GNK and then deacylated by NAGA, which
Figure 2. Synthetic analogues of 5SGlcNAc (3) are metabolized within
cells, leading to decreased O-GlcNAc levels in cells. a) Possible
metabolism of 5SGlcNR analogues (7–17) by NAGA prior to their
entry into the HBP. b) Synthetic analogues (7–17) bearing various
N-acyl R groups. c) Effects of analogues on the O-GlcNAc levels of
HEK293 cells. C= vehicle (PBS alone).
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we found to display remarkable substrate tolerance. The
resulting common intermediate, 5SGlcNH2-6-PO4 (6-PO4), is
then assimilated via the HBP to form UDP-5SGlcNAc (4),
which leads to metabolic inhibition of OGT and decreased
O-GlcNAc levels in tissues.
Previous efforts to use Ac45SGlcNAc (3-OAc) in vivo in
mammals failed because of its poor aqueous solubility. We
therefore evaluated whether these new water-soluble meta-
bolic OGT inhibitors could be used in vivo. Accordingly, we
dosed mice by intraperitoneal (IP) delivery with our most
cell-active compound 12. A concentration-dependent
decrease in spleen O-GlcNAc levels was observed upon
treatment with 12, with apparent effects at even 3 mgkg@1
(Figure S5a). Compound 12 (300 mgkg@1) decreased the
spleen O-GlcNAc levels over time with maximal inhibition
by 8 h, which was maintained for at least 48 h (Figure S5b).
Compound 12 reduced O-GlcNAc levels in the kidneys, lungs,
fat, pancreas, heart, spleen, and muscle tissue but not in the
blood or brain (Figure S5c). Mice injected with high doses of
12 (300 mgkg@1) became lethargic, which is a known conse-
quence of low leptin levels.[9] A second injection of
300 mgkg@1 on a second day caused mice to be moribund,
and we discontinued treatment. We therefore dosed mice IP
with a lower dose of 12 (50 mgkg@1, n= 3) and found reduced
O-GlcNAc levels in various tissues 16 h after dosing but no
effects on brain, liver, pancreas, and kidney (Figure 4a,b and
Figure S6a–c). The O-GlcNAc levels had returned to baseline
levels after 16 h (Figure 4a). Metabolic inhibitor 12 therefore
acts in vivo to reversibly lower O-GlcNAcylation in various
tissue types.
Notably, others have shown that Ac45SGlcNAc (3-OAc)
appears to be able to inhibit other glycosyltransferases in cell
lines.[5b] We found, however, by lectin blot assessment that 12
induced no apparent changes in other forms of protein
Figure 3. 5SGlcNR analogues are sequentially processed in cells by
GlcNAc kinase (GNK) and, likely, N-acetylglucosamine-6-phosphate-de-
N-acetylase (NAGA) to generate 5SGlcNH2-6PO4 (6-PO4). a) Nucleo-
tide sugar analysis of cells treated with selected inhibitors indicated
that all of the 5SGlcNR analogues tested (3-OAc, 7, 8, and 12) were
converted within cells into two new nucleotide sugars, indistinguish-
able from synthetically prepared UDP-5SGlcNAc (4) and UDP-5SGal-
NAc. b) 5SGlcNR analogues were phosphorylated by GNK in vitro.
c) 5SGlcNR-6-phosphates were not substrates for AGM or AGX but
were readily hydrolyzed in vitro by NAGA to produce 5SGlcNH2-6PO4
(6-PO4).
Figure 4. Dosing of mice with 50 mgkg@1 5SGlcNHex (12) reduced the
O-GlcNAc levels and impaired the secretion of the hormone leptin.
a) Skeletal muscle from mice dosed with 50 mgkg@1 of 12 showed
a transient reduction in O-GlcNAc levels by immunoblot analysis
(CTD110.6). b) Leptin levels as measured by ELISA decreased in mice
dosed with 12 to a minimum at 16 h. c) Dosing with 12 decreased
O-GlcNAc and Sp1 levels to a minimum at 16 h in fat pad tissue.
d) Compound 12 lowered GlcNAc-induced leptin secretion from 3T3-
L1 adipocytes. Results are given as the mean:SEM of three independ-
ent samples (n=3). Each independent sample was tested in duplicate;
symbols denote statistical significance (*p<0.05, **p<0.01,
***p<0.001 compared to control; Student’s t-test).
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glycosylation in all tissues tested (Figure S7) even at a dose of
300 mgkg@1 after 48 h, which is consistent with a recent report
on the use of the parent compound Ac45SGlcNAc (3-OAc) in
cells.[10]
Curiously, we observed that mice treated with either low
or high doses (50–300 mgkg@1) of 12 exhibited engorged
stomachs that were full of rodent chow after 16 h (Figure S8).
As lethargy and excessive food consumption (hyperphagia)
are seen in mice deficient in leptin signaling,[11] we measured
the serum leptin concentration of animals treated with
50 mgkg@1 of 12 (Figure 4b). Their leptin levels dropped
transiently to a minimum at 16 h (Figure 4b), consistent with
the engorged stomachs.[9, 12] The leptin levels were also lower
in mice treated with a high dose of 12 (300 mgkg@1; Fig-
ure S9). We therefore hypothesized that OGT inhibition
might impair leptin production (Figure S10).
To test this hypothesis, we used 3T3-L1 adipocytes and
found that these cells secreted less leptin when treated with
either 12 (Figure 4d) or Ac45SGlcNAc (3-OAc; Figure S11)
without affecting glucose uptake. Notably, the transcription
factors C/EBP-a, -b, and Sp1 all regulate leptin production.
Compound 12 lowered the levels of these known O-Glc-
NAcylated proteins in adipocytes (Figures S9) and in mice
(Figure S6d). These collective data are consistent with OGT
acting as a nutrient sensor in a process coupling HBP flux to
leptin levels (Figure S10).
We envision that future studies to detail dosing regimens
with 12 will be important to explore the effects of decreased
O-GlcNAc levels on various physiological processes. Experi-
ments will also be needed to detail the mechanistic links
between reduced O-GlcNAc levels due to in vivo OGT
inhibition, impaired leptin secretion, and apparent hyper-
phagia. However, our data provide the first direct correlation
between decreased O-GlcNAc levels and impaired leptin
production in vivo. Our findings are in accord with studies
showing that reduced O-GlcNAc lowers levels of Sp1 in
cells[6f, 13] and that OGT plays a pivitol role in fat tissues.[14]
Notably, these data also suggest that regulation of leptin by
O-GlcNAc is bidirectional in vivo as overexpression of
OGT,[3] knockout of OGA,[15] and metabolic upregulation of
UDP GlcNAc levels[16] all increase leptin expression.
In summary, we have described convenient new com-
pounds to inhibit OGT in cells and in vivo. Strikingly,
inhibition of OGT with 5SGlcNHex (12) provides support
for the hypothesis that reduced O-GlcNAc levels signal
impaired nutrient supply in mammals. We expect that these
observations will stimulate activity in the development of
additional metabolic OGT inhibitors. Moreover, we envision
that this chemical strategy of metabolic OGT inhibition will
serve as a valuable complement to using genetic methods in
various rodent models to accelerate studies to understand the
in vivo roles of O-GlcNAc in mammals.
Experimental Section
Please see the Supporting Information for full experimental
procedures. All experiments carried out on animals were approved by
the University Animal Care Committee of SFU.
Acknowledgements
K. Buettner and M. Dearden from the SFU animal care
facility are thanked for their expert advice and assistance. S.
Yuzwa is thanked for early studies on leptin levels. This work
was supported by a grant from the Natural Sciences and
Engineering Research Council of Canada (NSERC). D.J.V. is
a scholar of the Michael Smith Foundation of Health
Research (MSFHR) and a Tier II Canada Research Chair
in Chemical Glycobiology. T.M.G. was supported by a Sir
Henry Wellcome postdoctoral fellowship (WT082572) and
a Research Career Development Fellowship from the Well-
come Trust (WT095828).
Conflict of interest
These compounds are the subject matter of a provisional
patent application on inhibitors of O-GlcNAc transferase.
D.J.V., L.D., and T.M.G. are inventors on this patent
application.
Keywords: glycoproteins · inhibitors · leptin · nucleotide sugars ·
thiosugars
How to cite: Angew. Chem. Int. Ed. 2018, 57, 7644–7648
Angew. Chem. 2018, 130, 7770–7774
[1] a) C. R. Torres, G. W. Hart, J. Biol. Chem. 1984, 259, 3308 – 3317;
b) G. W. Hart, M. P. Housley, C. Slawson, Nature 2007, 446,
1017 – 1022.
[2] a) C. M. Ferrer, V. L. Sodi, M. J. Reginato, J. Mol. Biol. 2016,
428, 3282 – 3294; b) O. Lagerlof, J. E. Slocomb, I. Hong, Y.
Aponte, S. Blackshaw, G. W. Hart, R. L. Huganir, Science 2016,
351, 1293 – 1296; c) S. Dassanayaka, S. P. Jones, Pharmacol. Ther.
2014, 142, 62 – 71.
[3] D. A. McClain, W. A. Lubas, R. C. Cooksey, M. Hazel, G. J.
Parker, D. C. Love, J. A. Hanover, Proc. Natl. Acad. Sci. USA
2002, 99, 10695 – 10699.
[4] a) C. F. Teo, E. G. El-Karim, L. Wells, Glycobiology 2016, 26,
1198 – 1208; b) M. S. Macauley, Y. He, T. M. Gloster, K. A.
Stubbs, G. J. Davies, D. J. Vocadlo, Chem. Biol. 2010, 17, 937 –
948; c) M. S.Macauley, X. Shan, S. A. Yuzwa, T. M. Gloster, D. J.
Vocadlo, Chem. Biol. 2010, 17, 949 – 958; d) P. J. Stivers, L.
Harmonay, A. Hicks, H. Mehmet, M. Morris, G. M. Robinson,
P. R. Strack, M. J. Savage, D. M. Zaller, I. Zwierzynski, P. E.
Brandish, PLoS One 2015, 10, e0145151.
[5] a) J. Jiang, M. B. Lazarus, L. Pasquina, P. Sliz, S. Walker, Nat.
Chem. Biol. 2011, 8, 72 – 77; b) R. F. Ortiz-Meoz, J. Jiang, M. B.
Lazarus, M. Orman, J. Janetzko, C. Fan, D. Y. Duveau, Z. W.
Tan, C. J. Thomas, S. Walker, ACS Chem. Biol. 2015, 10, 1392 –
1397; c) T. M. Gloster, W. F. Zandberg, J. E. Heinonen, D. L.
Shen, L. Deng, D. J. Vocadlo,Nat. Chem. Biol. 2011, 7, 174 – 181;
d) B. J. Gross, B. C. Kraybill, S. Walker, J. Am. Chem. Soc. 2005,
127, 14588 – 14589; e) R. Trapannone, K. Rafie, D. M. van Aal-
ten, Biochem. Soc. Trans. 2016, 44, 88 – 93.
[6] a) S. Olivier-Van Stichelen, L. Drougat, V. Dehennaut, I. El Ya-
zidi-Belkoura, C. Guinez, A. M. Mir, J. C. Michalski, A. S.
Vercoutter-Edouart, T. Lefebvre, Oncogenesis 2012, 1, e36;
b) P. J. Lund, J. E. Elias, M. M. Davis, J. Immunol. 2016, 197,
3086 – 3098; c) M. Swamy, S. Pathak, K. M. Grzes, S. Damerow,
L. V. Sinclair, D. M. van Aalten, D. A. Cantrell, Nat. Immunol.
2016, 17, 712 – 720; d) F. Doll, A. Buntz, A. K. Spate, V. F.
Angewandte
ChemieCommunications
7647Angew. Chem. Int. Ed. 2018, 57, 7644 –7648 T 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
Schart, A. Timper, W. Schrimpf, C. R. Hauck, A. Zumbusch, V.
Wittmann, Angew. Chem. Int. Ed. 2016, 55, 2262 – 2266; Angew.
Chem. 2016, 128, 2303 – 2308; e) C. M. Speakman, T. C. Domke,
W. Wongpaiboonwattana, K. Sanders, M. Mudaliar, D. M.
van Aalten, G. J. Barton, M. P. Stavridis, Stem Cells 2014, 32,
2605 – 2615; f) Y. Zhu, T. W. Liu, S. Cecioni, R. Eskandari, W. F.
Zandberg, D. J. Vocadlo, Nat. Chem. Biol. 2015, 11, 319 – 325;
g) Y. Zhu, T. W. Liu, Z. Madden, S. A. Yuzwa, K. Murray, S.
Cecioni, N. Zachara, D. J. Vocadlo, J. Mol. Cell Biol. 2016, 8, 2 –
16; h) W. Lin, L. Gao, X. Chen, ChemBioChem 2015, 16, 2571 –
2575; i) P. H. Chen, T. J. Smith, J. Wu, P. F. Siesser, B. J. Bisnett,
F. Khan, M. Hogue, E. Soderblom, F. Tang, J. R. Marks, M. B.
Major, B. M. Swarts, M. Boyce, J. T. Chi, EMBO J. 2017, 36,
2233 – 2250; j) P. S. Banerjee, J. Ma, G. W. Hart, Proc. Natl.
Acad. Sci. USA 2015, 112, 6050 – 6055.
[7] A. K. Bergfeld, O. M. Pearce, S. L. Diaz, R. Lawrence, D. J.
Vocadlo, B. Choudhury, J. D. Esko, A. Varki, J. Biol. Chem. 2012,
287, 28898 – 28916.
[8] a) M. S. Macauley, J. Chan, W. F. Zandberg, Y. He, G. E.
Whitworth, K. A. Stubbs, S. A. Yuzwa, A. J. Bennet, A. Varki,
G. J. Davies, D. J. Vocadlo, J. Biol. Chem. 2012, 287, 28882 –
28897; b) D. J. Vocadlo, H. C. Hang, E. J. Kim, J. A. Hanover,
C. R. Bertozzi, Proc. Natl. Acad. Sci. USA 2003, 100, 9116 – 9121.
[9] M. A. Pelleymounter, M. J. Cullen, M. B. Baker, R. Hecht, D.
Winters, T. Boone, F. Collins, Science 1995, 269, 540 – 543.
[10] L. M. Andres, I. W. Blong, A. C. Evans, N. G. Rumachik, T.
Yamaguchi, N. D. Pham, P. Thompson, J. J. Kohler, C. R.
Bertozzi, ACS Chem. Biol. 2017, 12, 2030 – 2039.
[11] Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, J. M.
Friedman, Nature 1994, 372, 425 – 432.
[12] J. L. Halaas, K. S. Gajiwala, M. Maffei, S. L. Cohen, B. T. Chait,
D. Rabinowitz, R. L. Lallone, S. K. Burley, J. M. Friedman,
Science 1995, 269, 543 – 546.
[13] I. Han, J. E. Kudlow, Mol. Cell. Biol. 1997, 17, 2550 – 2558.
[14] H. B. Ruan, M. O. Dietrich, Z. W. Liu, M. R. Zimmer, M. D. Li,
J. P. Singh, K. Zhang, R. Yin, J. Wu, T. L. Horvath, X. Yang, Cell
2014, 159, 306 – 317.
[15] C. Keembiyehetty, D. C. Love, K. R. Harwood, O. Gavrilova,
M. E. Comly, J. A. Hanover, J. Biol. Chem. 2015, 290, 7097 –
7113.
[16] a) J. Wang, R. Liu, M. Hawkins, N. Barzilai, L. Rossetti, Nature
1998, 393, 684 – 688; b) E. E. Wollaston-Hayden, R. B. Harris, B.
Liu, R. Bridger, Y. Xu, L. Wells, Front. Endocrinol. 2014, 5, 223.
Manuscript received: March 16, 2018
Accepted manuscript online: May 14, 2018
Version of record online: May 24, 2018
Angewandte
ChemieCommunications
7648 www.angewandte.org T 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2018, 57, 7644 –7648
